ProfileGDS5678 / 1435863_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 90% 90% 88% 90% 89% 89% 89% 90% 90% 89% 89% 87% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.7446488
GSM967853U87-EV human glioblastoma xenograft - Control 27.2130290
GSM967854U87-EV human glioblastoma xenograft - Control 37.1987290
GSM967855U87-EV human glioblastoma xenograft - Control 47.0428888
GSM967856U87-EV human glioblastoma xenograft - Control 57.2226490
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.8774489
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7981189
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.9958989
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.1463290
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1617390
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.0651189
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.1043589
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.6218687
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.1926990